MOTS-C is a prescription therapy used for metabolic and energy support.

Patients seeking support for metabolic and energy support may qualify after evaluation by a licensed provider.

Yes. MOTS-C is a compounded peptide that requires a valid prescription from a licensed provider. A telehealth consultation and medical intake are required before dispensing to ensure MOTS-C is appropriate for your health history, goals, and current medications.

MOTS-C is generally well-tolerated at therapeutic doses. Injection site reactions including transient redness, mild swelling, or discomfort may occur with subcutaneous administration. Some patients report mild fatigue or lightheadedness during initial dosing, which typically resolves as the body adjusts. Transient changes in appetite or energy levels have been noted, consistent with MOTS-C's influence on AMPK activation and metabolic regulation. As with any peptide therapy, individual responses vary. Report any unusual or persistent symptoms to your provider.

MOTS-C is not appropriate for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. Patients with a history of hormone-sensitive cancers or active malignancy should not use MOTS-C without thorough oncological and provider evaluation. Those with severe hepatic or renal impairment require individualized review before starting, as these conditions may affect peptide metabolism and clearance. MOTS-C has not been studied in pediatric populations and is not indicated for patients under 18. Disclose your full medical history, current medications, and any history of malignancy before starting treatment.

Because MOTS-C activates AMPK and improves insulin sensitivity, patients on antidiabetic medications including metformin, insulin, or GLP-1 agonists should use caution, as additive glucose-lowering effects may increase the risk of hypoglycemia. MOTS-C influences mitochondrial energy metabolism and the folate-methionine cycle. Patients on methotrexate, folate supplements, or B12 therapy should disclose this before starting. Those on anti-inflammatory medications or immunomodulatory agents should discuss concomitant use with their provider, as MOTS-C exerts NF-κB suppressive effects that may be additive. Always provide a complete medication list to your provider before beginning treatment.

Patients with a history of any malignancy should not use MOTS-C without thorough oncological and provider evaluation. Those with type 1 or type 2 diabetes require close provider monitoring, as MOTS-C's AMPK activation and insulin-sensitizing effects may significantly alter glucose regulation and medication requirements. Patients with cardiovascular disease, metabolic syndrome, or obesity may benefit from MOTS-C but require individualized dosing and provider supervision given its potent effects on mitochondrial function and lipid metabolism. Those with autoimmune conditions, active infections, or significant hepatic or renal impairment require careful provider review before starting. Your provider requires a complete medical history before prescribing and will determine whether MOTS-C is appropriate given your individual health profile.